CYPs have a number of disadvantages, including low stability or inactivity. The Austrian Centre of Industrial Biotechnology (acib), together with an consortium within the EU-project ROBOX, created lyophilised CYP biocatalysts that have proven to be very promising for a variety of industrial applications for the pharma, flavour and fragrance, and material science industries.
PD-1+ T cells trigger pulmonary fibrosis
Latest NewsA team of researchers from the US and the UK have found that CD4-positive T cells harboring the PD-1 immune checkpoint protein can promote excessive connective tissue formation in lung cells.
Roche’s Tecentriq prolongs OS in SCLC
Latest NewsCancer immunotherapy has been heralded as paradigm change in cancer treatment. Now, Roche’s US arm Genentech announced that the company’s anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) improved survival by only two months as first-line treatment for patients with the rare lung cancer SCLC.
Ysios Capital appoints Guillem Laporta
AppointmentsYsios Capital, a biotechnology venture capital firm in Spain, today announced that it has appointed Guillem Laporta as Principal.
CRISPR-gene drive safely kills mosquitos
Latest NewsA new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
ROBOX makes storable CYPs
Sponsored PublicationsCYPs have a number of disadvantages, including low stability or inactivity. The Austrian Centre of Industrial Biotechnology (acib), together with an consortium within the EU-project ROBOX, created lyophilised CYP biocatalysts that have proven to be very promising for a variety of industrial applications for the pharma, flavour and fragrance, and material science industries.
Managing complexity to bring drugs to clinic faster
BackgroundIntegrating the disparate stages of drug development is the most time and cost-efficient way of turning a promising candidate compound into a pharmaceutical product. A CDMO that offers coordinated end-to-end services simplifies oversight.
CHMP with new Chair – 13 meds recommended
Latest NewsThe CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.
European biotech companies enter IPO prep course
Latest NewsEuropean stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies – this time also including companies from Germany, Italy, Spain, and Switzerland.
Novo Nordisk reveals details about its R&D transformation
Latest NewsNovo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China.
Turning cancer into a chronic disease
OpinionFollowing last year’s approval by the US FDA, the EU’s EMA has now also approved the first two T-cell-based immunotherapies against certain types of cancer. This marks the ultimate proof-of-concept for the acceptance of patient-individualised cellular immunotherapies. The regulatory authorities have moved fast, together with the companies and manufacturers, to bring these products to patients as quickly as possible. This is a good start but what does the future hold?